and are two weight-loss and diabetes drug shares which have been on fully totally different trajectories. For the reason that begin of 2025, LLY is up practically 30%, whereas NVO has plummeted greater than 30%.
This comes as Eli Lilly has taken huge market share from Novo. In its newest quarter, Eli Lilly posted income progress of 56% yr over yr (YOY). For the full-year 2026, the midpoint of Lilly’s steering implies progress of 28% YOY.
In the meantime, Novo expects its fixed foreign money gross sales to fall by 5% to 13% YOY in 2026, a large step down from progress of 36% in 2023. A lot of the distinction of their income progress is because of Lilly’s GLP-1 tirzepatide. Branded as Mounjaro and Zepbound, the drug induces round 47% extra weight reduction than Novo’s semaglutide.
Regardless of their battle, the businesses just lately acquired information that each can cheer about. The Meals and Drug Administration has proposed to exclude tirzepatide and semaglutide from its 503B bulk checklist. Right here’s what which means for Lilly and Novo going ahead.
FDA Appears to Cease 503B Compounding for Good—Lilly and Novo Rating
When an accredited drug is in scarcity, the FDA permits 503A compounding pharmacies and 503B outsourcing services to compound copies of the drug. After the FDA added tirzepatide and semaglutide to the scarcity checklist in 2022, firms like constructed companies round compounding GLP-1s. Hims has utilized each 503A and 503B services to supply its medication prior to now.
Shortages for each medication ended between 2024 and 2025, however Hims operated in a authorized grey space to proceed promoting. In keeping with Pharmacy Occasions, the proposal’s passing would “foreclose any future pathway” for 503B services to compound the medication, “even within the occasion of a brand new scarcity designation.” In different phrases, there can be no going again.
For Lilly and Novo, this is able to be a transparent win. Compounders have siphoned off demand for his or her medication that will in any other case go to them. The proposal would take away the flexibility of 503B services to do that sooner or later. For 503A, that future alternative remains to be there, though it’s technically prohibited to promote these medication beneath that standing, because the shortages are over. Nonetheless, Hims clearly demonstrates how regulators haven’t totally enforced this.
Notably, Novo shares rose by 4.8% on the day of this April 30 announcement, displaying that buyers noticed it as a significant piece of optimistic information. Lilly rose 9.8% that day, and although the announcement coincided with the agency’s extremely spectacular earnings report, it’s possible that the information additionally contributed to Lilly’s vital acquire.
Hims Positive aspects as Traders Weigh Compounding Regulation
For Hims and Hers, the profit is extra nuanced however nonetheless reliable. The corporate just lately signed a take care of Novo, permitting it to formally promote semaglutide and oral semaglutide. With this proposal, the group of compounders that Hims competes with weakens.
With its Novo settlement, Hims can promote branded (AKA non-compounded) variations of the corporate’s GLP-1s. Which means the FDA proposal shouldn’t restrict Hims’s capacity to promote Novo’s medication. Nevertheless, it could influence the flexibility of some compounders to do the identical sooner or later, placing Hims in a stronger place.
In a press release to Reuters, a Hims & Hers spokesperson mentioned the corporate doesn’t count on the proposal to influence its enterprise. Hims famous that “there aren’t any GLP-1s compounded by 503B services accessible by our platform.” Hims shares rose by roughly 3.2% on the day of the proposal.
Hims can even proceed to promote Lilly’s medication. Nevertheless, the agency doesn’t have the identical kind of settlement that it does with Novo. Accessing Lilly’s medication by Hims acts extra like a referral association, directing customers to Lilly. Hims’ personal announcement says, “Entry to Zepbound and Foundayo doesn’t suggest a partnership or affiliation with Eli Lilly and Firm.”
As a result of this, it’s not possible that Hims receives any direct monetary profit from providing Lilly’s medication. Nevertheless, Hims could possibly acquire or retain members who would have regarded to different telehealth platforms to entry Lilly’s therapies.
Lilly Continues to Dominate the GLP-1 Area
Total, Eli Lilly and Novo ought to get added safety for his or her helpful GLP-1 medication. The proposal shouldn’t be closing at this level. Nevertheless, because it got here from the decision-maker itself (the FDA), it’s more likely to be enacted.
Hims is an under-the-radar winner from the proposal on the semaglutide facet, given its formally established relationship with Novo.
Nevertheless, amongst these names, Eli Lilly is clearly within the strongest place. The corporate demonstrated that it doesn’t have to make a take care of Hims like Novo did. Moderately, it’s taking all of the spoils from its top-performing weight-loss and diabetes drugs.
Authentic Publish
